Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Jazz Pharmaceuticals is a specialty biopharmaceutical company focused on neuroscience and oncology, with its flagship narcolepsy drug Xywav/Xyrem generating approximately 60% of revenue. The company operates a diversified portfolio including Epidiolex for epilepsy, Rylaze for acute lymphoblastic leukemia, and Zepzelca for small cell lung cancer, with strong commercial presence in North America and expanding European operations. Competitive position is anchored by patent-protected specialty products in niche therapeutic areas with high barriers to entry and limited generic competition through 2030.
Jazz operates a high-margin specialty pharmaceutical model targeting rare diseases and orphan indications with limited competition. Pricing power derives from patent protection (Xywav protected through 2033), orphan drug exclusivity, and treatment of severe conditions with few alternatives. The company maintains a specialized sales force targeting sleep specialists, neurologists, and oncologists rather than competing in primary care. Gross margins near 89% reflect minimal manufacturing costs relative to pricing, while operating leverage comes from spreading fixed R&D and SG&A across a growing revenue base. The business model emphasizes lifecycle management (Xywav replacing Xyrem to extend franchise), geographic expansion (European launches), and strategic M&A to acquire late-stage assets.
Xywav market share gains and pricing - conversion from legacy Xyrem franchise and penetration in idiopathic hypersomnia indication
Oncology portfolio growth trajectory - Zepzelca second-line small cell lung cancer uptake and potential label expansions
Pipeline clinical trial readouts - particularly zanidatamab (bispecific antibody) Phase 3 data in biliary tract cancer expected 2026-2027
Generic competition timeline for key products - particularly Epidiolex patent challenges and Xyrem authorized generic dynamics
M&A activity and capital deployment - company has historically acquired late-stage assets to supplement organic growth
Patent cliff risk concentration - Xywav/Xyrem franchise representing 60% of revenue faces potential generic entry post-2033, requiring successful pipeline execution and M&A to offset
Regulatory pricing pressure - ongoing political focus on drug pricing reform, particularly for high-cost specialty products, could impact net pricing through government negotiation or rebate expansion
Payer reimbursement evolution - shift toward value-based contracts and outcomes-based pricing in specialty pharma may compress margins if clinical differentiation is insufficient
Narcolepsy market competition - potential new entrants with novel mechanisms (orexin agonists in development by multiple companies) could erode Xywav dominance in core franchise
Oncology portfolio commoditization - Zepzelca and other oncology assets face intense competition from checkpoint inhibitors, ADCs, and targeted therapies with superior efficacy profiles
Biosimilar and generic challenges - Epidiolex faces CBD-based generic competition, and authorized generic dynamics for Xyrem create pricing pressure on oxybate franchise
Debt maturity profile - $5.6B gross debt with staggered maturities requires refinancing in potentially higher rate environment, though strong FCF provides deleveraging capacity
Negative ROE of -9.3% reflects accumulated deficit from historical losses and acquisition accounting, though improving profitability trajectory suggests normalization
Acquisition integration risk - company's growth strategy depends on successful M&A execution and integration of acquired products into commercial infrastructure
low - Specialty pharmaceutical demand is largely non-discretionary as products treat serious medical conditions (narcolepsy, epilepsy, cancer) where patients and physicians prioritize efficacy over cost. Revenue resilience demonstrated through economic cycles, though payer mix shifts (Medicaid expansion during recessions) can pressure net pricing. Prescription volumes show minimal correlation to GDP growth.
Rising rates create moderate headwinds through two channels: (1) higher debt service costs on $5.6B gross debt (mix of fixed and floating rate), though interest coverage remains strong at 8-10x EBITDA, and (2) valuation multiple compression as growth stocks re-rate versus risk-free alternatives. However, strong FCF generation ($1.3B annually) enables debt reduction and reduces refinancing risk. Rate increases have minimal impact on operating business as customers are primarily insured patients rather than rate-sensitive consumers.
Moderate exposure through commercial payer reimbursement dynamics. Tightening credit conditions can pressure private insurers to implement stricter prior authorization requirements or shift patients to lower-cost alternatives, though specialty products with limited substitutes face less pressure. Company maintains patient assistance programs to bridge coverage gaps. Debt/EBITDA of approximately 2.5x is manageable but limits financial flexibility for large acquisitions during credit stress.
value - Stock trades at 2.5x P/S and generates 13.1% FCF yield, attracting value investors focused on cash generation and potential multiple re-rating. Negative ROE and moderate growth (6.1% revenue growth) limit appeal to pure growth investors, while lack of dividend excludes income-focused shareholders. Recent 41.5% six-month return suggests momentum investors have entered, but core holder base consists of healthcare specialists focused on patent runway, pipeline optionality, and M&A catalysts.
moderate-to-high - Specialty pharma stocks exhibit elevated volatility driven by binary clinical trial outcomes, regulatory decisions, and patent litigation. Stock has demonstrated 25% one-year return with -4.2% three-month pullback, indicating episodic volatility around catalysts. Beta likely in 1.0-1.3 range given healthcare sector exposure and mid-cap positioning. Elevated EV/EBITDA of 56.1x suggests market is pricing significant growth expectations, creating downside risk if execution falters.